UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE TO

(Amendment No. 3)

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934

OLINK HOLDING AB (PUBL)
(Name of Subject Company (Issuer))

ORION ACQUISITION AB
(Offeror)
a direct, wholly owned subsidiary of

THERMO FISHER SCIENTIFIC INC.
(Ultimate Parent of Offeror)


Common Shares, quota value SEK 2.431906612623020 per Share
American Depositary Shares (“ADSs”), each representing one Common Share,
quota value SEK 2.431906612623020 per Share
(Title of Class of Securities)

680710100*
(CUSIP Number of Class of Securities)

Michael A. Boxer
Senior Vice President and General Counsel
Thermo Fisher Scientific Inc.
168 Third Avenue
Waltham, Massachusetts 02451
Telephone:  (781) 622-1000
(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)


Copies to:

Ting S. Chen
Bethany A. Pfalzgraf
Cravath, Swaine & Moore LLP
Worldwide Plaza
825 Eighth Avenue
New York, NY 10019
+1 (212) 474-1000

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

 
third-party tender offer subject to Rule 14d-1.
 
issuer tender offer subject to Rule 13e-4.
 
going-private transaction subject to Rule 13e-3.
 
amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:  ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 
Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
 
Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)


*This CUSIP number is assigned to the Subject Company’s American Depositary Shares, each representing one (1) Common Share.



This Amendment No. 3 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (as amended and together with any subsequent amendments and supplements thereto, the “Schedule TO”), filed with the U.S. Securities and Exchange Commission on October 31, 2023, by Thermo Fisher Scientific Inc., a Delaware corporation (“Parent”). The Schedule TO relates to the tender offer (the “Offer”) by Orion Acquisition AB, a private limited liability company organized under the laws of Sweden, a direct, wholly owned subsidiary of Parent, to purchase all of the outstanding common shares, quota value SEK 2.431906612623020 per share (the “Shares”) and all of the outstanding American Depositary Shares, each representing one Share (the “ADSs”), of Olink Holding AB (publ), Reg. No. 559189-7755, a public limited liability company organized under the laws of Sweden, in exchange for $26.00 per Share (that is not represented by an ADS) or $26.00 per ADS, as applicable, in cash, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated as of October 31, 2023, the related ADS Letter of Transmittal and the related Acceptance Form for Shares, copies of each of which are attached to the Schedule TO as exhibits (a)(1)(A), (a)(1)(B) and (a)(1)(C), respectively.

Except to the extent specifically provided in this Amendment, the information set forth in the Schedule TO remains unchanged. This Amendment is being filed to amend and supplement the Item set forth below.

Item 12. Exhibits.

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibits:

Exhibit
No.
 
Description
 
 
(a)(5)(L)
 


SIGNATURES

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 
Thermo Fisher Scientific Inc.
 
     
 
By:
/s/ Michael A. Boxer
 
   
Name:
Michael A. Boxer
 
   
Title:
Senior Vice President and General Counsel
 
   
Date:
November 13, 2023
 
     
 
Orion Acquisition AB, a direct, wholly owned subsidiary of Parent
 
     
 
By:
/s/ Anthony H. Smith
 
   
Name:
Anthony H. Smith
 
   
Title:
Director
 
   
Date:
November 13, 2023
 



Exhibit (a)(5)(K)

Message to Current and Former Employees with Global Share Accounts:

Orion Acquisition AB (“Buyer”), a direct, wholly owned subsidiary of Thermo Fisher Scientific Inc. (“Thermo Fisher”), commenced on October 31, 2023, a tender offer (the “Offer”) for all the outstanding common shares and American Depositary Shares (“ADSs”) of Olink Holding AB (publ) (“Olink” or the “Company”).

The consideration to be paid through the Offer is USD $26.00 per common share or ADS (such amount, the “Offer Consideration”).

After careful consideration, the board of directors of the Company (the “Olink Board”) has recommended that Olink shareholders accept the Offer and tender their common shares and ADSs to the Buyer pursuant to the Offer.  In addition, as part of the transaction, Summa Equity AB, the parent of Olink’s largest shareholder, and additional Olink shareholders and management, in the aggregate holding approximately 66% of Olink’s outstanding common shares, have entered into support agreements with Thermo Fisher agreeing to tender into the tender offer. 

In order to tender your common shares or ADSs into the Offer, you must submit instructions through the task below by 12 pm GMT on 29 November 2023.  If you hold common shares or ADSs outside of Equity Gateway, you should check with your broker, dealer or other securities intermediary for their specific cut-off time.  If certain conditions to the Offer are not met, the Offer will be extended.  Any extension to the Offer period will be separately announced.

Assuming all of the conditions of the Offer have been met (or, if applicable, waived), Buyer will, promptly following the expiration time of the Offer, accept for payment all common shares and ADSs validly tendered and not properly withdrawn pursuant to the Offer. The consideration to be paid in exchange for the tender of common shares and ADSs is expected to be paid on or about the third business day after the date that the Offer is consummated and all common shares and ADSs validly tendered and not withdrawn have been transferred to Buyer. If you have not provided your bank information to Global Shares, the cash consideration for common shares and ADSs that you validly tender will be sent to the Company’s payroll department for pay-out to you.

Shareholders who choose not to accept the Offer will NOT receive cash consideration in the timeline set forth above. If the Offer is consummated and all common shares and ADSs validly tendered and not properly withdrawn have been transferred to Buyer, and Buyer has acquired more than 90% of all outstanding common shares, Buyer will commence compulsory redemption proceedings to redeem the remaining outstanding common shares in accordance with the Swedish Companies Act. After completion of such compulsory redemption proceedings, which are expected to take several months, shareholders who did not previously tender their common shares and ADSs in the Offer will be paid the same cash price as was paid in the Offer (unless special cause so dictates, in which case the redemption price may differ from the Offer Consideration).



Please refer to the Offer materials previously published, including the Offer to Purchase, for additional information regarding the Offer.

For questions, please contact Georgeson LLC, as information agent for the Offer, at +1 866 821 2550 (U.S. toll-free), +1 781 222 0033 (outside U.S. & Canada) or +46 846 007 389 (Sweden) or via email at olink@georgeson.com.

***

Additional Information and Where to Find It

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any common shares or American Depositary Shares of Olink or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or the Buyer has filed with the U.S. Securities and Exchange Commission (“SEC”). The terms and conditions of the tender offer are published in, and the offer to purchase common shares and American Depositary Shares of Olink is made only pursuant to, the offer document and related offer materials prepared by Thermo Fisher and the Buyer and is filed with the SEC in a tender offer statement on Schedule TO. In addition, Olink has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer.

THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE ADS LETTER OF TRANSMITTAL, THE ACCEPTANCE FORM FOR SHARES AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF OLINK ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON SHARES AND AMERICAN DEPOSITARY SHARES.

The tender offer materials, including the offer to purchase, the related ADS letter of transmittal and acceptance form for shares and certain other tender offer documents, and the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Olink, may be obtained free of charge at the SEC’s website at www.sec.gov, at Olink’s website https://investors.olink.com/investor-relations, at Thermo Fisher’s website at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. In addition, Thermo Fisher’s tender offer statement and other documents it will file with the SEC will be available at https://ir.thermofisher.com/investors.

Exhibit (a)(5)(L)

Email to Current and Former Employees with Global Share Accounts:

Orion Acquisition AB (“Buyer”), a direct, wholly owned subsidiary of Thermo Fisher Scientific Inc. (“Thermo Fisher”), commenced on October 31, 2023, a tender offer (the “Offer”) for all the outstanding common shares and American Depositary Shares (“ADSs”) of Olink Holding AB (publ) (“Olink” or the “Company”).

The consideration to be paid through the Offer is USD $26.00 per common share or ADS (such amount, the “Offer Consideration”).

After careful consideration, the board of directors of the Company (the “Olink Board”) has recommended that Olink shareholders accept the Offer and tender their common shares and ADSs to the Buyer pursuant to the Offer.  In addition, as part of the transaction, Summa Equity AB, the parent of Olink’s largest shareholder, and additional Olink shareholders and management, in the aggregate holding approximately 66% of Olink’s outstanding common shares, have entered into support agreements with Thermo Fisher agreeing to tender into the tender offer. 

In order to tender your common shares or ADSs into the Offer, you must submit instructions through your Global Shares account by 12 pm GMT on 29 November 2023.  If you hold common shares or ADSs outside of Equity Gateway, you should check with your broker, dealer or other securities intermediary for their specific cut-off time.  If certain conditions to the Offer are not met, the Offer will be extended.  Any extension to the Offer period will be separately announced.

Assuming all of the conditions of the Offer have been met (or, if applicable, waived), Buyer will, promptly following the expiration time of the Offer, accept for payment all common shares and ADSs validly tendered and not properly withdrawn pursuant to the Offer. The consideration to be paid in exchange for the tender of common shares and ADSs is expected to be paid on or about the third business day after the date that the Offer is consummated and all common shares and ADSs validly tendered and not withdrawn have been transferred to Buyer. If you have not provided your bank information to Global Shares, the cash consideration for common shares and ADSs that you validly tender will be sent to the Company’s payroll department for pay-out to you.

Shareholders who choose not to accept the Offer will NOT receive cash consideration in the timeline set forth above. If the Offer is consummated and all common shares and ADSs validly tendered and not properly withdrawn have been transferred to Buyer, and Buyer has acquired more than 90% of all outstanding common shares, Buyer will commence compulsory redemption proceedings to redeem the remaining outstanding common shares in accordance with the Swedish Companies Act. After completion of such compulsory redemption proceedings, which are expected to take several months, shareholders who did not previously tender their common shares and ADSs in the Offer will be paid the same cash price as was paid in the Offer (unless special cause so dictates, in which case the redemption price may differ from the Offer Consideration).



Please refer to the Offer materials previously published, including the Offer to Purchase, for additional information regarding the Offer.

For questions, please contact Georgeson LLC, as information agent for the Offer, at +1 866 821 2550 (U.S. toll-free), +1 781 222 0033 (outside U.S. & Canada) or +46 846 007 389 (Sweden) or via email at olink@georgeson.com.

***

Additional Information and Where to Find It

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any common shares or American Depositary Shares of Olink or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or the Buyer has filed with the U.S. Securities and Exchange Commission (“SEC”). The terms and conditions of the tender offer are published in, and the offer to purchase common shares and American Depositary Shares of Olink is made only pursuant to, the offer document and related offer materials prepared by Thermo Fisher and the Buyer and is filed with the SEC in a tender offer statement on Schedule TO. In addition, Olink has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer.

THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE ADS LETTER OF TRANSMITTAL, THE ACCEPTANCE FORM FOR SHARES AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF OLINK ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON SHARES AND AMERICAN DEPOSITARY SHARES.

The tender offer materials, including the offer to purchase, the related ADS letter of transmittal and acceptance form for shares and certain other tender offer documents, and the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Olink, may be obtained free of charge at the SEC’s website at www.sec.gov, at Olink’s website https://investors.olink.com/investor-relations, at Thermo Fisher’s website at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. In addition, Thermo Fisher’s tender offer statement and other documents it will file with the SEC will be available at https://ir.thermofisher.com/investors.


Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Thermo Fisher Scientific Charts.
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Thermo Fisher Scientific Charts.